CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Hematologic Malignancies Medical Crossfire in NYC on July 14th! Register today!
<< View More Conferences
2018 European Hematology Association Congress
Oncology Conference Multimedia
View more videos >>
Dr. Sallman on APR-246 Plus Azacitidine in TP53-Mutant MDS and AML
Dr. Mato Discusses the Safety and Efficacy of Umbralisib in CLL
Dr. Cortes on the Results of Quizartinib in Relapsed/Refractory AML
Oncology Conference Articles
Tisagenlecleucel Demonstrates Durable Response Beyond 1 Year in DLBCL
At a median follow-up of 14.1 months, the chimeric antigen receptor T-cell therapy tisagenlecleucel achieved an objective response rate of 52% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.
Elotuzumab/Pomalidomide Prolongs PFS in Pretreated Multiple Myeloma
The addition of elotuzumab to pomalidomide and dexamethasone cut the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.
Upfront Duvelisib Plus FCR Shows Promise in Younger Patients With CLL
The combination of duvelisib and fludarabine-cyclophosphamide-rituximab demonstrated efficacy as a frontline treatment for younger patients with chronic lymphocytic leukemia.
Quizartinib Extends Survival in FLT3-ITD+ Relapsed/Refractory AML
Quizartinib reduced the risk of disease progression or death by 24% compared with salvage chemotherapy in patients with
-ITD–positive relapsed/refractory acute myeloid leukemia after first-line treatment with or without hematopoietic stem cell transplantation.
Polatuzumab Vedotin Plus BR Demonstrates Higher PET-CR in DLBCL
The addition of polatuzumab vedotin to bendamustine and rituximab induced a higher rate of complete responses by PET scan compared with BR alone in patients with relapsed/refractory diffuse large B-cell lymphoma.
CD22 CAR T-cell Therapy Effective After CD19 CAR Therapy Failure in Children With B-ALL
A CAR T-cell therapy specific for CD22 was safe and provided high response rates for pediatric patients with B-cell acute lymphoblastic leukemia who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment.
Compound CAR T-Cell Therapy Shows Promise for AML
A compound CLL1/CD33-targeted CAR T-cell therapy showed a complete remission with minimal residual disease (MRD) negativity in a single-patient case study from an ongoing phase I study for relapsed/refractory acute myeloid leukemia.
PET-Guided De-escalation Effective in Advanced Hodgkin Lymphoma
PET can be safely used to guide treatment in patients with untreated advanced-stage classical Hodgkin lymphoma after 2 cycles of upfront de-escalated BEACOPP.
Obinutuzumab/Chlorambucil Solidified as Frontline CLL Option
The combination of obinutuzumab and chlorambucil reduced the risk of death by 24% versus rituximab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.
FDA Approval in CRC, Priority Review in HCC, Encouraging Data in Myeloma Trial, and More
Ramalingam Reflects on Recent Advances in SCLC
Progress Continues in EGFR+ NSCLC Paradigm
Defining Precision Cancer Medicine the Right Way
MCL Researcher Highlights Future of CAR T-Cell Therapy, Other Approaches
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.